About us
biocon ltd., asia's premier biopharmaceutical company, is committed to ensure a global right to healthcare by addressing the worldwide need for safe, effective and affordable biotherapeutics. We have harnessed the power of biotechnology through affordable innovation to enhance access to new and differentiated therapies for diseases that are chronic, where medical needs are largely unmet.
the company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in india and other emerging markets. Today, we are india's largest and fully-integrated biopharmaceutical company that develops, manufactures and supplies advanced, life-saving biopharmaceuticals for diabetes, cancer and autoimmune conditions at price points that make them affordable and thus accessible.
as an innovation-led organization focused on providing affordable access, we have leveraged our inherent strengths in advanced science to develop, manufacture and deliver a rich portfolio of small molecules apis & formulations and complex biologics - both novels and biosimilars - including monoclonal antibodies (mabs), rh-insulin and insulin analogs.

About us
biocon ltd., asia's premier biopharmaceutical company, is committed to ensure a global right to healthcare by addressing the worldwide need for safe, effective and affordable biotherapeutics. We have harnessed the power of biotechnology through affordable innovation to enhance access to new and differentiated therapies for diseases that are chronic, where medical needs are largely unmet.
the company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in india and other emerging markets. Today, we are india's largest and fully-integrated biopharmaceutical company that develops, manufactures and supplies advanced, life-saving biopharmaceuticals for diabetes, cancer and autoimmune conditions at price points that make them affordable and thus accessible.
as an innovation-led organization focused on providing affordable access, we have leveraged our inherent strengths in advanced science to develop, manufacture and deliver a rich portfolio of small molecules apis & formulations and complex biologics - both novels and biosimilars - including monoclonal antibodies (mabs), rh-insulin and insulin analogs.